QC
CORT icon

Quent Capital’s Corcept Therapeutics CORT Stock Holding History

Quent Capital’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.35K Buy
83
+63
+315% +$2.36K ﹤0.01% 1332
2025
Q4 		$696 Sell
20
-24
-55% -$1.89K ﹤0.01% 1496
2025
Q3 		$3.66K Buy
+44
New +$3.18K ﹤0.01% 1194

Other funds holding CORT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Quent Capital's CORT Position: Q1 2026 in Review

Quent Capital increased its Corcept Therapeutics (CORT) stake by 315% in Q1 2026, buying an estimated $2.36K and bringing the position to 83 shares worth $3.35K. The position accounts for ﹤0.01% of the portfolio, ranked #1332.

Quent Capital first reported a position in CORT in Q3 2025 and has held it in 3 quarters since. The position peaked at $3.66K in Q3 2025. 351 funds tracked by Wall St. Rank hold CORT as of Q1 2026.

  • Quent Capital held 83 shares of Corcept Therapeutics worth $3.35K as of Q1 2026.
  • Quent Capital bought 63 Corcept Therapeutics shares in Q1 2026, an estimated $2.36K.
  • Corcept Therapeutics made up ﹤0.01% of Quent Capital's portfolio in Q1 2026, its #1332 holding.
  • Quent Capital first reported a position in Corcept Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Quent Capital's Corcept Therapeutics position peaked at $3.66K in Q3 2025.
  • 351 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2026.

Based on Quent Capital's 13F filing for Q1 2026, filed 28 Apr 2026.